June 2015. Volume 11. Number 2

Prophylactically administered azitrhomycin could modestly reduce the incidence of bronchopulmonary dysplasia

 
 
 
 
 
 
 
 
 
 
Rating: 0 (0 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

AVC | Critically appraised articles

Nair V, Loganathan P, Soraisham AS. Azithromycin and other macrolides for prevention of bronchopulmonary dysplasia: a systematic review and meta-analysis. Neonatology. 2014;106:337-47.
Reviewers: Perdikidis Olivieri L1, Buñuel Álvarez JC2.
1EAP Juncal. Torrejón de Ardoz. Madrid. España.
2CS de Villamayor de Gállego. Servicio Aragonés de Salud. Villamayor de Gállego. Zaragoza. España.
Correspondence: Leo Perdikidis Olivieri. Email: lperdikidis@gmail.com
Reception date: 23/04/2015
Acceptance date: 28/04/2015
Publication date: 06/05/2015

Abstract

Author’s conclusions: azithromycin (AZT), when administered prophylactically, is associated with a decrease of bronchopulmonary dysplasia (BPD) and in the composite variable DBP / mortality in preterm infants (RNP). This effect disappeared by including other macrolides in the analysis. Because the pharmacokinetics of these drugs in RNP is not well known and because of its possible adverse effects, more studies are needed before recommending the routine use of AZT in RNP.

Reviewers’ comments: AZT, administered prophylactically, has a modest effectiveness in reducing the incidence of BPD. There are no available data on the safety of AZT in preterm or on what subset of RNP would benefit most from this intervention. In view of the currently available evidence it seems prudent not to use this drug systematically in RNP.

How to cite this article

Perdikidi Olivieri L, Buñuel Álvarez JC. La azitromicina administrada de forma profiláctica podría reducir moderadamente la incidencia de displasia broncopulmonar. Evid Pediatr. 2015;11:29.

AVC | Critically appraised articles

Nair V, Loganathan P, Soraisham AS. Azithromycin and other macrolides for prevention of bronchopulmonary dysplasia: a systematic review and meta-analysis. Neonatology. 2014;106:337-47.
Reviewers: Perdikidis Olivieri L1, Buñuel Álvarez JC2.
1EAP Juncal. Torrejón de Ardoz. Madrid. España.
2CS de Villamayor de Gállego. Servicio Aragonés de Salud. Villamayor de Gállego. Zaragoza. España.
Correspondence: Leo Perdikidis Olivieri. Email: lperdikidis@gmail.com
Reception date: 23/04/2015
Acceptance date: 28/04/2015
Publication date: 06/05/2015

How to cite this article

Perdikidi Olivieri L, Buñuel Álvarez JC. La azitromicina administrada de forma profiláctica podría reducir moderadamente la incidencia de displasia broncopulmonar. Evid Pediatr. 2015;11:29.

References

  1. Tapia JL, Agost D, Alegria A, Standen J, Escobar M, Grandi C, et al. Bronchopulmonary dysplasia: incidence, risk factors and resource utilization in a population of South American very low birth weight infants. J Pediatr (Rio J). 2006;82:15-20.
  2. Cunha GS, Mezzacappa Filho F, Ribeiro JD. Fatores maternos e neonatais na incidência de displasia broncopulmonar em recém-nascidos de muito baixo peso. J Pediatr (Rio J). 2003;79:550-6.
  3. Lowe J, Watkins WJ, Edwards MO, Spiller OB, Jacqz-Aigrain E, Kotecha SJ, et al. Association between pulmonary ureaplasma colonization and bronchopulmonary dysplasia in preterm infants: updated systematic review and meta-analysis. Pediatr Infect Dis J. 2014;33:697-702.
  4. Cotten CM, Taylor S, Stoll B, Goldberg RN, Hansen NI, Sánchez PJ, et al. Prolonged duration of initial empirical antibiotic treatment is associated with increased rates of necrotizing enterocolitis and death for extremely low birth weight infants. Pediatrics. 2009;123:58-66.
  5. Kenyon S, Boulvain M, Neilson JP. Antibiotics for preterm rupture of membranes. Cochrane Database Syst Rev. 2013;12:CD001058.

Related Articles

CA | Displasia broncopulmonar y azitromicina, ¿una solución o un nuevo problema?

Sánchez Luna M. Displasia broncopulmonar y azitromicina, ¿una solución o un nuevo problema? Evid Pediatr. 2015;11:32.
06/05/2015

Linked Comment

CA | Displasia broncopulmonar y azitromicina, ¿una solución o un nuevo problema?

Sánchez Luna M. Displasia broncopulmonar y azitromicina, ¿una solución o un nuevo problema? Evid Pediatr. 2015;11:32.